What is Cancer Prevention Pharmaceuticals EV-to-Revenue?
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cancer Prevention Pharmaceuticals's enterprise value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 was $1.16 Mil. Therefore, Cancer Prevention Pharmaceuticals's EV-to-Revenue for today is 0.00.
The historical rank and industry rank for Cancer Prevention Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
CPP's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.375 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Cancer Prevention Pharmaceuticals EV-to-Revenue Chart
Competitive Comparison of Cancer Prevention Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cancer Prevention Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cancer Prevention Pharmaceuticals's EV-to-Revenue falls into.
Cancer Prevention Pharmaceuticals EV-to-Revenue Calculation
Cancer Prevention Pharmaceuticals's current Enterprise Value is $0.00 Mil.
Cancer Prevention Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cancer Prevention Pharmaceuticals (AMEX:CPP) EV-to-Revenue Explanation
Cancer Prevention Pharmaceuticals's share price for today is $25.91.
Cancer Prevention Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.22.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cancer Prevention Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Business Description
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.
Cancer Prevention Pharmaceuticals (Cancer Prevention Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPP has been successfully added to your